Cancer screening in the elderly population

Cancer surgery in the elderly

The proportions both of elderly patients in the world and of elderly patients with cancer are both increasing. In the evaluation of these patients, physiologic age, and not chronologic age, should be carefully considered in the decision-making process prior to both cancer screening and cancer treatment in an effort to avoid ageism. Many tools exist to help the practitioner determine the physiologic age of the patient, which allows for more appropriate and more individualized risk stratification, both in the pre- and postoperative periods as patients are evaluated for surgical treatments and monitored for surgical complications, respectively. During and after operations in the oncogeriatric populations, physiologic changes occuring that accompany aging include impaired stress response, increased senescence, and decreased immunity, all three of which impact the risk/benefit ratio associated with cancer surgery in the elderly.

Preventive health care in the elderly population: a guide for practicing physicians

Preventive medicine provides important benefits to all persons, including older adults; however, these benefits may be seen more clearly in younger adults than in older persons. Smoking cessation, proper nutrition, exercise, and immunizations are important regardless of age. The prevalence of illness increases as we age; at the same time, life expectancy decreases. All physicians and patients should consider the potential benefits of screening and treatment vs conservative management. We discuss lifestyle recommendations such as smoking cessation, exercise, and good nutrition, as well as the role of screening for cardiovascular disease, cancer, and sensory and other disorders. These recommendations are derived from evidence-based guidelines when available; issues not associated with established guidelines are discussed on the basis of best current thinking.

Colorectal cancer surveillance after age 65 years

BACKGROUND

It would be valuable to determine whether or not asymptomatic patients 60 to 65 years of age with normal colonoscopies should continue to undergo serial colorectal cancer surveillance examinations.

METHODS

Data were obtained from retrospective review of our existing database. Additional data were obtained from patients' medical records, office charts, and pathology reports. In situ endoscopic measurements were performed using a biopsy forceps that was 7 mm when fully extended.

RESULTS

Over the past 25 years, 699 asymptomatic patients between 60 and 65 years of age underwent colonoscopies which revealed no pathology. As part of their routine continuing colorectal surveillance and without any prior abnormal endoscopic findings, 56 of these patients underwent a total of 123 colonoscopies after age 65. Thirty-seven patients (66%) had surveillance colonoscopies that continued to be normal while 13 patients (23%) were diagnosed with colorectal adenomas and 6 patients (11%) were found to have hyperplastic polyps. No cancers were discovered.

CONCLUSIONS

Patients over the age of 65 should continue to undergo colorectal surveillance even if prior examinations have been negative.

Updates in surgical oncology for elderly patients

Elderly patients affected by solid tumours are frequently encountered on the surgical ward. Prejudice regarding operative risks and long term outcomes may alter their surgical management. Large series of elderly cancer subjects have been analysed and conclusive data are now available, to better tailor their management. Specific epidemiological data are presented in this review, screening programs critically considered, treatment procedures discussed, and the effectiveness of follow-up protocols is analysed together with cost effectiveness issues. Quality of life issues should not be neglected, and a continuous educational endeavour targeted at specialists and general practitioners is desirable.

Prevention of cancer in the older person

Both primary and secondary cancer prevention may improve cancer control among older persons. Although chemoprevention of cancer is feasible, the agents currently used for chemoprevention have several complications. As a result, the use of these substances should be individualized based on risk-benefit ratio. It is reasonable to implement screening for cancer of the breast and of the large bowel in persons with a life expectancy of 5 years and longer. No definite recommendation may be issued at present related to screening for prostate, lung, and cervical cancer. Ongoing clinical trials may answer some of these questions.

Geriatric oncology: challenges for the new century

The management of cancer in the older aged person represents one of the major immediate challenges of medicine. The response to this challenge involves answers to the following questions: I. Who is old? Currently. 70 years of age may he considered the lower limit of senescence because the majority of age-related changes occur after this age. Individual estimates of life expectancy and functional reserve may be obtained by a comprehensive and time-consuming multidimensional geriatric assessment. The current instrument may be fine-tuned and new instruments, including laboratory tests of ageing. may be developed. 2. Why do older persons develop more cancer? It is clear that ageing tissues are more susceptible to late-stage carcinogen. Older persons may represent a natural monitor system for new environmental carcinogens, and may also represent a fruitful ground to study the late stages of carcinogenesis. 3. Is cancer different in younger and older persons? Clearly. the behaviour of some tumors. including acute myeloid leukaemia, non-Hodgkin's lymphoma and breast cancer change with the age of the patient. The mechanisms of these changes that may involve both the tumour cell and the tumour host are poorly understood. 4. Can cancer he prevented in older individuals? Chemoprevention offers a new horizon of possibilities for cancer prevention: older persons may benefit most from chemoprevention due to increased susceptibility to environmental carcinogens. Screening tests may become more accurate in older individuals due to increased prevalence of cancer. hut may he less beneficial due to more limited patient life expectancy. 5. Do older persons benefit from cytotoxic treatment? The answer to this question partly stands on proper patient selection. partly on the development of safer forms of cancer treatment and prudent use of antidotes to chemotherapy toxicity. 6. What is the cost of treating older cancer patients? The treatment of older patients is generally more costly. This cost should be assessed against the cost of not treating cancer and promoting functional dependence. which by itself is extremely costly. 7. What are the endpoints of clinical trials in older cancer patients? With more limited life expectancy. the effect of treatment on quality of life is paramount. Reliable assessment of quality of life is essential for interpreting clinical trials in older individuals. 2000 Elsevier Science Ltd. All rights reserved.